Selective RET Kinase Inhibitors and Lung Cancer
The New England journal of medicine（2023）
摘要
Inhibiting the RET Tyrosine Kinase in NSCLC This editorial describes the science behind a phase 3 trial of selpercatinib to treat patients with RET fusion-positive non-small-cell lung cancer.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要